Header image

Plenary #3 - ISCoS Lecture: Dr Masaya Nakamura

Track 1
Track 2
Track 3
Thursday, September 3, 2020
10:00 AM - 10:55 AM
Auditorium - Track 1


Agenda Item Image
Prof Masaya Nakamura
Professor & Chair
Keio University School Of Medicine

Regenerative medicine for spinal cord injury using iPS cells

10:00 AM - 10:55 AM


Spinal cord injuries (SCI) result in devastating loss of function, because spinal cord of human beings never regenerates after injury. People believed in this dogma for a long time. There is an emerging hope for regeneration-based therapy of the damaged spinal cord due to the progress of neuroscience and regenerative medicine including stem cell biology. Stimulated by the 2012 Nobel Prize in Physiology or Medicine awarded for Shinya Yamanaka and Sir John Gurdon, there is an increasing interest in the iPS cells (iPSCs) and reprogramming technologies in medical science. While iPS cells are expected to open new era providing enormous opportunities in the biomedical sciences in terms of cell therapies for regenerative medicine, safety-related concerns for iPS cell-based cell therapy should be resolved prior to the clinical application of iPSCs. Especially, some previous reports indicated risk factors for the use of iPSCs, such as genetic and epigenetic abnormalities that could take place during reprogramming or maintenance in subsequent cell culture. Of particular relevance is the potential tumorigenicity and immunogenicity associated with iPSC-based cell therapy. In this symposium, I would like to summarize previous efforts in the field as well as the current status of iPSC-based cell therapy for repair of the damaged central nervous system, with a special emphasis on SCI. Furthermore, I would like to explain our upcoming clinical trial of iPSC-derived neural stem cell transplantation for sub-acute SCI patients.


Masaya Nakamura, MD and PhD is Professor and Chair, Department of Orthopedic Surgery (2015 – present) and Vice Dean, Keio University School of Medicine (2017 – present). He received his PhD from Keio University in 1995. He specializes in spine and spinal cord surgery as well as stem cell biology, especially regenerative medicine for spinal cord injury for 30 years. He completed Phase I/II clinical trial of hepatocyte growth factor for acute spinal cord injury last year. Now, he is focusing on clinical trials of cell therapy for sub-acute and chronic spinal cord injury using iPS cells. He has published more than 600 papers in English. He received the First award of the Japanese Society for Regenerative Medicine and 51th Baelz prize in 2014. He is Member of Scientific Committee of International Spinal Cord Society, Board member and chair of Committee of Regenerative medicine for spinal cord injury of Japanese Medical Society of Spinal Cord Lesion, Board member of Japanese Society for Regenerative Medicine.